B.1.1.7

Hemp, Inc.’s CBDA and CBGA Products on Sale Now

Retrieved on: 
Tuesday, July 19, 2022
Safe harbor, U.S. Securities and Exchange Commission, News, Disease, Lists of schools in England, CBD, Science, Hemp, Cannabis, Vice, Securities Act of 1933, Infection, Industry, Company, Nature, OSU, Vaccine, Q&A, CBGA, Research, SEC, DCG, Medical College of Georgia Institute of Molecular Medicine and Genetics, Inflammation, Securities Exchange Act of 1934, THC, COVID, CBDA, OTC Exchange of India, Health, Journal of Cellular and Molecular Medicine, Security (finance), Interview, Sunlight, The O.C., COVID-19, Drug Quality and Security Act, SEO, OTC, Degenerative disease, Severe acute respiratory syndrome coronavirus 2, B.1.1.7, Capsule, Inhalation, GLOBE, Apelin, United Kingdom, Human, Sale, Medical college, Journal, Cannabinoid, Molecular medicine, Animal, Dietary supplement, Public relations, Bloomberg

The Company announced its CBDA and CBGA capsules are in stock and available for sale.

Key Points: 
  • The Company announced its CBDA and CBGA capsules are in stock and available for sale.
  • Many anticipate OSUs study will generate a huge rush-to-market but Hemp, Inc. is already ahead of the curve, as its CBD line can easily be reformulated with CBDA and CBGA.
  • According to another source , CBGA (cannabigerolic acid) is the "mother cannabinoid" of popular compounds such as CBD and THC.
  • CBGA converts to other precursor compounds, one of which is CBDA (cannabidiolic acid).

Microbix Presenting Omicron Test Control Results at CVS

Retrieved on: 
Friday, April 29, 2022
QAP (Colombia), Antigen, TSX, Sale, FDA, RUO, GLOBE, Poster, Name, Health Canada, Organization, CVS, TGA, COVID, U.S. FDA, Company, Goal, IVD, News, B.1.1.7, Engineering, ISO 9001, Society, OTCQX, Medical device, Review, American Society for Microbiology, CE, Infection, Severe acute respiratory syndrome coronavirus 2, Health, Vaccine, Omicron

At CVS, Microbix will be exhibiting alongside leading diagnostics firms that provide tests for detection of COVID and other infectious diseases.

Key Points: 
  • At CVS, Microbix will be exhibiting alongside leading diagnostics firms that provide tests for detection of COVID and other infectious diseases.
  • Microbix will also review performance of its QAPs to support quality management of testing for infection with Omicron (the B.1.1.529 variant of SARS-CoV-2).
  • Its poster presentation is titled Use of SARS-CoV-2 Omicron External Controls for Verifying the Performance of Primary and Reflex SARS-CoV-2 Molecular Detection Methodologies.
  • The poster will be made available on Microbixs website (https://microbix.com) and from CVS following its presentation.

Akston Biosciences Announces Publication in Vaccine of Positive Data for a Room Temperature Protein Subunit COVID-19 Vaccine

Retrieved on: 
Tuesday, February 8, 2022
Research, Infectious Diseases, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, SARS, Merck & Co., Martek Biosciences Corporation, Research, Autoimmune disease, GMP, Â, Patient, Seroconversion, SmartCell Technology, Severe acute respiratory syndrome coronavirus 2, CEO, COVID, Therapy, Coronavirus, DPH, B.1.1.7, Merck, Infection, RBD, COVID-19, Vaccine, Pharmaceutical industry, Vaccine, AKS-452, Akston Biosciences, AKS-452, AKSTON BIOSCIENCES

Akston Biosciences Corporation , a developer of new classes of biologic therapeutics, announced publication of positive results from a 60-subject, open-label, Phase I trial of AKS-452, its shelf stable protein subunit COVID-19 vaccine candidate.

Key Points: 
  • Akston Biosciences Corporation , a developer of new classes of biologic therapeutics, announced publication of positive results from a 60-subject, open-label, Phase I trial of AKS-452, its shelf stable protein subunit COVID-19 vaccine candidate.
  • The trial met all primary and secondary endpoints, indicating minimal reactogenicity and optimized immunogenicity.
  • A recombinant subunit vaccine, AKS-452 comprises an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain (RBD) antigen that is engineered to preserve effectiveness against viral variants.
  • Akston Biosciences Corporation leverages its novel fusion protein platform to develop and manufacture new classes of biologics, including vaccines, ultra-long-acting insulins, and autoimmune disease therapies.

Bruker Expects its FluoroType® SARS-CoV-2 varID Q PCR Assay to Reliably Detect and Tentatively Differentiate Omicron (B.1.1.529) Variant

Retrieved on: 
Thursday, December 2, 2021
Medical Devices, Health, Infectious Diseases, Hospitals, Pharmaceutical, Biotechnology, N501Y, PCR, Viral load, WHO, Alpha, Severe acute respiratory syndrome coronavirus 2, Bruker, B.1.1.7, Nasdaq, CP, Corporation, Multimedia, XT, Typesetting, Bruker Molecular Diagnostics, Bruker Corporation, BRUKER MOLECULAR DIAGNOSTICS, BRUKER CORPORATION

View the full release here: https://www.businesswire.com/news/home/20211202005759/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211202005759/en/
    FluoroType SARS-CoV-2 varID Q PCR Kit (Photo: Business Wire)
    FluoroType SARS-CoV-2 varID Q is a multiplexed CE-IVD marked PCR assay for the detection and quantification of all major SARS-CoV-2 variants, based on Brukers proprietary LiquidArray technology.
  • In addition, the assay simultaneously detects the S-gene mutations Del69-70 and N501Y, which are expected to be clear indications that the variant is Omicron (B.1.1.529).
  • Using the FluoroType SARS-CoV-2 varID Q assay allows the user to run a screening tool for detecting SARS-CoV-2, viral load and an early indication of the Omicron variant.
  • Moreover, Bruker is pleased to confirm that their full range of other FluoroType SARS-CoV-2 assays are also expected to reliably detect the Omicron variant (B.1.1.529).

BetterLife Successfully Completes Phase 1 and Initiates Phase 2 Clinical Trials with Interferon Alpha-2b in COVID-19 Patients in Chile

Retrieved on: 
Monday, November 29, 2021
Medical school, Patient, Degenerative disease, Rheumatology, Safety, Coronavirus, Social, Hospital, Health, Severe acute respiratory syndrome coronavirus 2, Principal investigator, Economics, Escuela Superior Politecnica del Litoral, Duke University School of Medicine, B.1.1.7, University, College of Arts and Sciences, Therapy, Agriculture, COVID-19, CSE, Theology, Research, School, GLOBE, Phase, Infection, Lists of diseases, Knowledge, Literature, Associate, Coro de la Pontificia Universidad Católica de Puerto Rico, Person, Immune system, Philosophy, Time, Pharmaceutical industry, Vaccine

Eighteen healthy subjects were enrolled in the Phase 1 portion of the IN2COVID trial (ClinicalTrials.gov Identifier: NCT04988217 ).

Key Points: 
  • Eighteen healthy subjects were enrolled in the Phase 1 portion of the IN2COVID trial (ClinicalTrials.gov Identifier: NCT04988217 ).
  • AP-003 demonstrated an excellent safety and tolerability profile and no serious adverse events were observed.
  • Dr. Eleanor Fish, one of the Principal Investigators of the trial, commented, I am confident that inhaled administration of interferon alpha-2b, AP-003 will prove to be an effective treatment against COVID-19.
  • With AP-003, there is the added advantage of a pathogen agnostic broad spectrum antiviral that may have therapeutic benefits for many respiratory virus infections.

QIAGEN reaffirms effectiveness of its SARS-CoV-2 PCR tests in light of the new coronavirus variant B.1.1.529

Retrieved on: 
Friday, November 26, 2021
Health, Medical Devices, Infectious Diseases, Genetics, Other Health, Pharmaceutical, Biotechnology, Patient, QIAGEN, GISAID, Coronavirus, Protein, CE, NYSE, PCR, Beta, Romolo Manissero, Alpha, Severe acute respiratory syndrome coronavirus 2, Virus, Knowledge, Gold standard (test), SEC, B.1.1.7, Solution, Blood, Budget, Vaccine, COVID-19, Database, GenBank, U.S. Securities and Exchange Commission, DNA, Research, Gamma, Real-time, Infection, United Kingdom, Polymerase chain reaction, RNA, Molecular diagnostics, QGEN, Automation, Life, Growth, Animal, Computer data storage

QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against the genetic mutations of the variant, which is known by its scientific name, B.1.1.529.

Key Points: 
  • QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against the genetic mutations of the variant, which is known by its scientific name, B.1.1.529.
  • QIAGEN also offers the offers the QIAstat-Dx Respiratory+ test in the U.S., Europe and other markets for detection of more than 20 respiratory illnesses, including COVID-19 infections.
  • QIAGEN offers tests worldwide for use on this system for detection of the SARS-CoV-2 virus.
  • QIAGEN has been closely monitoring and will continue to do so the performance of its PCR tests as new variants emerge in the global fight against the coronavirus pandemic.

Microbix Expands Pandemic Test Controls (QAPs™) Portfolio

Retrieved on: 
Wednesday, November 17, 2021
News, QAP (Colombia), IVD, PCR, Health Canada, Health, Antigen, Organization, Engineering, CEO, OTCQX, TGA, B.1.1.7, U.S. FDA, COVID, CE, United, Goal, COVID-19, Medical device, TSX, Company, GLOBE, Solution, Stock, VOC, Collection, Volatile organic compound, ISO 9001, FDA, Vaccine, Pharmaceutical industry

Microbixs QAPs portfolio now consists of 70 proprietary SKUs in the categories of respiratory, sexually-transmitted, and gastrointestinal infectious diseases.

Key Points: 
  • Microbixs QAPs portfolio now consists of 70 proprietary SKUs in the categories of respiratory, sexually-transmitted, and gastrointestinal infectious diseases.
  • Of that portfolio, 15 QAPs are available as REDx Controls for IVD use by clinical labs.
  • Such Microbix REDx QAPs help manage the accuracy of workflows to avoid the systemic errors that result in false-negative or false-positive test results.
  • Cameron Groome, CEO and President of Microbix, commented Microbix has been providing critical test ingredients to the diagnostics industry for over three decades.

Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021 BioCentury China Healthcare Summit

Retrieved on: 
Wednesday, November 17, 2021
People, Antibody-dependent enhancement, Safety, NIAID, Achievement, Foundation for the National Institutes of Health, Tsinghua University, AIDS Clinical Trials Group, Plasma, National Institute of Allergy and Infectious Diseases, Xinhui People's Hospital, Clinical trial, Infection, R, Hospital, HIV, B.1.1.7, National Medical Products Administration, Food, Senior, ACTG, Severe acute respiratory syndrome coronavirus 2, CDE, COVID-19, Epsilon, MDR, Regulation of tobacco by the U.S. Food and Drug Administration, National Institute, Hepatitis B, CNS, Center for Drug Evaluation and Research, Award, Company, Beta, Therapy, EUA, Death, AIDS, Central nervous system, XDR, Patient, NIH, Risk, FDA, NMPA, Pharmaceutical industry

The recognition is for the R&D achievements of Brii Bio's investigational monoclonal neutralizing antibody combination therapy, BRII-196/BRII-198 ("combination BRII-196/BRII-198"), for the treatment of COVID-19.

Key Points: 
  • The recognition is for the R&D achievements of Brii Bio's investigational monoclonal neutralizing antibody combination therapy, BRII-196/BRII-198 ("combination BRII-196/BRII-198"), for the treatment of COVID-19.
  • In parallel, the company has submitted the Phase 3 interim data to China Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA).
  • The BioCentury-Bayhelix China Healthcare Awards celebrate outstanding individuals and companies for their achievement and contribution to the local healthcare ecosystem.
  • R&D Achievement of the Year recognizes one company for a scientific discovery in China with direct impact to drug R&D or a significant achievement in pharmaceutical development milestones.

Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373

Retrieved on: 
Monday, November 15, 2021
Safety, Conversation, Financial condition report, Lymph, Health, Clinical trial, Infection, Zip Co Limited, Security (finance), Antigen presentation, European Union, Ministry, Disease, B.1.1.7, BLA, Coronavirus, Risk, European Medicines Agency, Union, Severe acute respiratory syndrome coronavirus 2, Biologics license application, COVID-19, Annual report, Serum Institute of India, Ministry of Food and Drug Safety, Global health, Partnership, MFDS, Biotechnology, U.S. Securities and Exchange Commission, Genetic engineering, SEC, Analysis, B cell, Result, Vaccination, COVAX, Nanoparticle, United Kingdom, NVAX, Novavax COVID-19 vaccine, Pharmaceutical industry, Vaccine

GAITHERSBURG, Md., Nov. 15, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited (SK bioscience), a biotechnology company in South Korea, today announced the submission of a Biologics License Application (BLA) for Novavax' COVID-19 vaccine to South Korea's Ministry of Food and Drug Safety (MFDS). NVX-CoV2373, Novavax' recombinant nanoparticle COVID-19 vaccine with Matrix-M™ adjuvant, is the first protein-based COVID-19 vaccine to be submitted for BLA in Korea.

Key Points: 
  • NVX-CoV2373, Novavax' recombinant nanoparticle COVID-19 vaccine with Matrix-M adjuvant, is the first protein-based COVID-19 vaccine to be submitted for BLA in Korea.
  • "Today's submission reflects the first BLA submission for full approval of our COVID-19 vaccine anywhere in the world, with more anticipated to follow," said Stanley C. Erck, President and Chief Executive Officer, Novavax.
  • In collaboration with Novavax, SK bioscience initiated the rolling submission process for NVX-CoV2373 to the MFDS in April of this year.
  • The completion of a BLA submission to the MFDS marks the final review stage for authorization of NVX-CoV2373 in Korea.

Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373

Retrieved on: 
Monday, November 15, 2021
Safety, Conversation, Financial condition report, Lymph, Health, Clinical trial, Infection, Zip Co Limited, Security (finance), Antigen presentation, European Union, Ministry, Disease, B.1.1.7, BLA, Coronavirus, Risk, European Medicines Agency, Union, Severe acute respiratory syndrome coronavirus 2, Biologics license application, COVID-19, Annual report, Serum Institute of India, Ministry of Food and Drug Safety, Global health, Partnership, MFDS, Biotechnology, U.S. Securities and Exchange Commission, Genetic engineering, SEC, Analysis, B cell, Result, Vaccination, COVAX, Nanoparticle, United Kingdom, NVAX, Novavax COVID-19 vaccine, Pharmaceutical industry, Vaccine

GAITHERSBURG, Md., Nov. 15, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited (SK bioscience), a biotechnology company in South Korea, today announced the submission of a Biologics License Application (BLA) for Novavax' COVID-19 vaccine to South Korea's Ministry of Food and Drug Safety (MFDS). NVX-CoV2373, Novavax' recombinant nanoparticle COVID-19 vaccine with Matrix-M™ adjuvant, is the first protein-based COVID-19 vaccine to be submitted for BLA in Korea.

Key Points: 
  • NVX-CoV2373, Novavax' recombinant nanoparticle COVID-19 vaccine with Matrix-M adjuvant, is the first protein-based COVID-19 vaccine to be submitted for BLA in Korea.
  • "Today's submission reflects the first BLA submission for full approval of our COVID-19 vaccine anywhere in the world, with more anticipated to follow," said Stanley C. Erck, President and Chief Executive Officer, Novavax.
  • In collaboration with Novavax, SK bioscience initiated the rolling submission process for NVX-CoV2373 to the MFDS in April of this year.
  • The completion of a BLA submission to the MFDS marks the final review stage for authorization of NVX-CoV2373 in Korea.